According to ThePrint, the Modi government has granted the green light to vaccine maker Serum Institute of India (SII) to manufacture and stockpile the Covovax vaccine. SII has already started manufacturing the vaccine, which is being developed in collaboration with Novavax in the United States.
As part of the COVAX vaccine alliance, SII has partnered with Novavax to manufacture and supply the vaccine in India and low- and middle-income nations. “The government has given the nod to SII to start manufacturing Covovax. It will be buying the entire quantity that SII has started stockpiling,” an industry source who is witness to the developments told ThePrint.
The decision was prompted by a chronic scarcity of vaccinations, which has forced the suspension of immunisation campaigns in numerous Indian states. The Modi government is scrambling to come up with new ideas to assist speed up the country’s vaccination campaign.
Covishield, Covaxin, and Russia’s Sputnik V are three vaccines now licenced for use by India’s pharma authority, the Drug Controller General of India (DCGI). Pfizer and Moderna, both of which are based in the United States, are in discussion with the federal government.